Medical Drugs News | Medical XPRT

Creative Enzymes Launches DSPE-PEG-Maleimide for Targeted Drug Delivery

Creative Enzymes, a professional enzyme provider located in New York, always hammers at researches and trials in order to provide customers with various enzymes as many as possible. The product manager of Creative Enzymes announced the launch of DSPE-PEG(5000) Maleimide and DSPE-PEG(2000) Maleimide, which can be used to synthesize functional conjugates. DSPE-PEG-Maleimide (DSPE-PEG-MAL) is a ...

Jun. 22, 2021

By Creative Enzymes

Thermo Fisher Scientific Introduces New Quick to Clinic Solution to Help Biologic Drug Developers Accelerate Preclinical Development at BIO Digital 2021

BIO DIGITAL 2021 – New and emerging biopharma companies working on early development can now leverage a better lab to clinic drug development solution designed to accelerate the journey from DNA to drug product. The enhanced Quick to Clinic solution from Thermo Fisher Scientific may help biopharma companies reach Phase I/First-In-Human trials and file for Investigational New Drug (IND) ...

Jun. 14, 2021

By Thermo Fisher Scientific, LIMS & Laboratory Software

Part of the Cell and Gene Therapy Catapult PAT Consortium

Imspex is delighted to be part of the ground-breaking process analytical technologies (PAT) consortium announced today by the Cell and Gene Therapy Catapult. The consortium of over 20 pharmaceutical companies, technology providers, therapy developers and charities is the largest in the cell and gene therapy space to date with a mission to co-create industry-specific solutions that improve ...

Jun. 9, 2021

By Imspex Diagnostics Ltd.

Creative Biolabs Upgrades Oncolytic Virus Product List for Immunotherapy Research

As early as around 1800, doctors discovered that certain cancer patients would have their symptoms reduced after being briefly infected with viruses. With the advancement of genetic engineering technology, the idea that viruses have the potential to improve and mediate immunotherapy has been established. Oncolytic viruses (OVs) are such kind of viruses that can replicate in tumor tissues, and ...

May 27, 2021

By Creative Biolabs

Creative Enzymes Upgrades Multiple Diagnostic Enzyme Products for Clinical and Diagnostic Research

Creative Enzymes, the world’s leading diagnostic enzyme production company, has been committed to providing customers with various enzyme products and services for medical and research diagnosis. Relying on its professional team and the most advanced technology, as well as high-quality products and services, it has gained solid reputation. Recently, Creative Enzymes has announced multiple ...

May 25, 2021

By Creative Enzymes

Thermo Fisher Scientific and University of California, San Francisco to Open Cell Therapy cGMP Manufacturing and Collaboration Center

Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, and the University of California, San Francisco (UCSF) today announced they have formed a strategic alliance to accelerate the development and manufacturing of cell-based therapies. Under the agreement, Thermo Fisher will build and operate a 44,000-square-foot, state-of-the-art cell therapy development, manufacturing ...

May 20, 2021

By Thermo Fisher Scientific, LIMS & Laboratory Software

Exosome Services at Creative Biolabs to Accelerate Lung Cancer Research

As the incidence and mortality of lung cancer rank among the highest all over the world, lung cancer diagnostics and treatment are the most researched paper topics. Research has reported that exosomes derived from lung cancer are the most promising biomarkers for early diagnosis, prognosis, and treatment of lung cancer. With years of experience in this field, Creative Biolabs provides exosome ...

Apr. 28, 2021

By Creative Biolabs

Thermo Fisher Scientific Recognizes Significance of FDA Approval of First CAR T Cell Immunotherapy for Multiple Myeloma with Donation to Leukemia and Lymphoma Society

Thermo Fisher Scientific Inc. has made a donation to the Leukemia & Lymphoma Society in recognition of the recent U.S. Food and Drug Administration approval of the first CAR T cell immunotherapy for multiple myeloma developed by Bristol Myers Squibb and bluebird bio. Abecma® (idecabtagene vicleucel; ide-cel) is a chimeric antigen receptor (CAR) T cell immunotherapy for the treatment of ...

Apr. 28, 2021

By Thermo Fisher Scientific, LIMS & Laboratory Software

GMP Pilot Program to Use the Span Smart Panel as Replacement for Traditional Meters

Green Mountain Power (GMP) launched a new pilot program to empower residential customers with new technology to simplify the transition to clean energy for home heating, vehicle charging, solar generation and energy storage. GMP is the first utility in the country to work with Span to offer the Span Smart Panel. The panel replaces the traditional home electric panel, and will give customers an ...

Apr. 22, 2021

By Smart Grid Observer

Neutralizing Antibody Development for SARS-CoV-2 Available at Creative Biolabs

The continuous spread of COVID-19 has become a threat to global health and even has led to a global economic crisis. Researchers arounad the world are putting tremendous effort toward developing vaccines and therapeutic drugs. Creative Biolabs has been dedicated to the discovery and development of different types of vaccines, including in silico vaccine, live attenuated and killed vaccine, ...

Apr. 16, 2021

By Creative Biolabs

Thermo Fisher Scientific to Acquire PPD, Inc., a Leading Clinical Research Organization

Establishes Thermo Fisher as a global leader in the attractive and high growth clinical research services industry Adds highly complementary services for the company's fastest growing end market Offers both meaningful cost and revenue synergies which will further accelerate growth Expected to be immediately and significantly accretive to Adjusted Earnings Per Share (EPS)¹ after close ...

Apr. 15, 2021

By Thermo Fisher Scientific, LIMS & Laboratory Software

Data from Eli Lilly’s COV-BARRIER trial shows baricitinib reduced deaths in hospitalised COVID-19 patients by 38%

The latest data published in Eli Lilly’s Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to date for a reduction in mortality in the COVID-19 patient population. ‍ Early in the pandemic, BenevolentAI researchers identified Baricitinib as a potential treatment for COVID-19 and published the hypothesis in The Lancet ...

Apr. 8, 2021

By Benevolent

Alloy Therapeutics Raises $75 Million in Series C Financing to Advance Collaborative Biotechnology Ecosystem

Alloy Therapeutics, a biotechnology ecosystem company empowering the global scientific community to make better medicines together, today announced the close of a $75 million Series C financing round. The round was led by 8VC, Presight Capital, and Peter Thiel with participation from new investors including Mubadala Capital, the asset management arm of Mubadala Investment Company, an unnamed ...

Apr. 2, 2021

By Alloy Therapeutics, Inc.

Amgen to Acquire Rodeo Therapeutics Corporation

Amgen Inc. (NASDAQ:AMGN) and Rodeo Therapeutics Corporation (Rodeo) today announced an agreement under which Amgen will acquire Rodeo, a privately held biopharmaceutical company based in Seattle that develops small-molecule therapies designed to promote regeneration and repair of multiple tissues. Rodeo's 15-PGDH program is a strong strategic fit with Amgen's inflammation portfolio and efforts to ...

Mar. 30, 2021

By Amgen Inc.

Lyra Therapeutics To Present Lantern Phase 2 Study Results For Lyr 210 In Oral Presentation At Cosm 2021 Virtual

Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases, today announced that the company will present Phase 2 results from the LANTERN study for LYR-210, the company’s lead product candidate ...

Mar. 29, 2021

By Lyra Therapeutics, Inc.

AVEO Oncology Announces Addition of FOTIVDA® (tivozanib) into National Comprehensive Cancer Network Clinical Practice Guidelines

AVEO Oncology (Nasdaq: AVEO) today announced that the National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines to include FOTIVDA® (tivozanib) as a recommended regimen for subsequent therapy. The subsequent therapy category follows the first-line treatment regimen recommendations for patients with clear cell histology renal cell carcinoma (ccRCC). On March 10, ...

Mar. 29, 2021

By AVEO Pharmaceuticals, Inc.

bit.bio CEO Dr Mark Kotter speaking about challenging biology at the TEDxCambridgeUniversity ‘Untangling networks’ event

On Saturday 20 March 2021, bit.bio CEO and founder Mark Kotter was a speaker at the TEDxCambridgeUniversity ‘Untangling networks’ event. Dr Kotter was speaking about his work as a neurosurgeon, stem cell biologist and an entrepreneur. Many of the conditions he faces as a doctor, whether they are cancers, genetic or degenerative conditions, need more than a scalpel and screws or ...

Mar. 26, 2021

By bit.bio

Immunai Acquires Dropprint Genomics and Strengthens Leadership Team with Experts in Immunology to Expand Target Discovery Capabilities

Immunai, a New York and Tel Aviv-based biotech company, announced its acquisition of Dropprint Genomics, a San Francisco-based single-cell genomics software company. Immunai is also expanding its executive leadership team and scientific advisory board with experts in immunology, single-cell technologies and machine learning. Both the acquisition and new hires will advance the company’s work ...

Mar. 25, 2021

By Immunai

Aspect Biosystems to Present at 2021 Virtual Cell & Gene Meeting on the Med

Aspect Biosystems, a privately held biotechnology company pioneering the development of bioprinted therapeutics, has announced that President & CEO Tamer Mohamed will present at the annual Cell & Gene Meeting on the Mediterranean to be held virtually April 6-9, 2021. This is the second time that the company will be presenting at this conference. The Business Development Team from Aspect ...

Mar. 24, 2021

By Aspect Biosystems Ltd.

Vaccitech Appoints Joseph Scheeren, PharmD, to its Board of Directors

Vaccitech Ltd (“Vaccitech”), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announces the appointment of Joseph Scheeren, PharmD, as an independent director to its Board of Directors (the “Board”). Dr. Scheeren succeeds ...

Mar. 22, 2021

By Vaccitech Limited